With the constant access and support from Dwavesys, our team is able harness the latest quantum annealing technology and design de novo molecules for a wide variety of diseases. Check out our case story! #biotech #QuantumComputing

Congrats to our portfolio company Menten AI for being the first company ever to design a peptide using quantum computing!

So excited to be part of #QHack2022 🧪💻 #QuantumComputing #Biotechnology

Our drug discovery efforts just got boosted by Xanadu ’s @pennylaneai We are excited to integrate this new technique into our drug design pipeline. prnewswire.com/news-releases/…

Bio-QML Challenge in the QHack Open Hackathon, meet you there 💻🧬💊 #biotech #QuantumComputing

“While quantum computing hardware capable of running these algorithms is still being developed, classical computing tools like NVIDIA cuQuantum are crucial for advancing quantum algorithm development” - Alexey Galda, Quantum Principal Scientist #biotech blogs.nvidia.com/blog/2022/05/3…

Come meet us at the American Peptide Symposium on June 28👋 Our Associate Director, Stephan Kudlacek, will be discussing Menten AI's most advanced generative AI platform for the design and optimization of cyclic peptides Visit our website menten.ai See you there!🎉

Ever wondered how multiple molecules fit together? 🤔 Check out Menten AI's work on predicting multibody molecular docking using a quantum annealer. #drugdiscovery #drugdesign #quantumcomputing #peptides #biotechnology lnkd.in/eCK4Js5z

Can you believe Menten AI achieved in vivo efficacy in only 4 weeks straight out of in silico design? 🧐 To find out how, don’t miss Dr. Stephan Kudlacek’s discussion at APS on June 26th! aps2023.org Not at APS? Don’t hesitate to reach out! menten.ai

Read about how in silico design can accelerate the development of peptides - a therapeutic modality that overcomes many limitations of small molecule and biologic drugs 🎯: lnkd.in/gcB3FE7u menten.ai

APS is happening now! Don’t miss the chance to meet Stephan Kudlacek and learn about how Menten AI utilizes Generative AI to advance #peptide drug discovery! 👋 #peptides #aritificialintelligence #machinelearning #drugdiscovery

The constrained peptide therapeutics market is expected to grow to $17.38 billion by 2040 at a CAGR of 38.94%! 🚀vs. ~9% CAGR for small molecules and biologics. Peptide therapeutics will become a major player.🏆 tinyurl.com/mrxk8hxx #peptides #drugdiscovery #generativeAI #ML

Drug discovery starts with having the right target ✅ Menten AI’s target assessment tool can uniquely model protein dynamics and identify novel hot-spot regions amenable for cyclic peptide design 🎯 #generativeai #artificialintelligence #drugdiscovery #peptides #biotechnology

Excited to announce our collaboration with Bristol Myers Squibb Bristol Myers Squibb applying Menten AI’s generative AI platform for peptide optimization. 🤝 #genai #drugdiscovery #partnerships t.ly/1KWK_

Menten AI is excited to share that our co-founder and Rosetta developer, Dr. Vikram Mulligan, published the first paper from his Masala project—an open-source suite designed to succeed Rosetta👏sciencedirect.com/science/chapte… A big step forward for protein and synthetic peptide design🚀

Wishing our partners, collaborators, and the broader scientific community a joyful holiday season! ✨ Thank you for being part of our journey in shaping the future of peptide therapeutics — we’re excited for what’s ahead in 2026. 🚀 #peptidetherapeutics #drugdiscovery #ai

We’re excited to be in San Francisco as we continue advancing peptide therapeutics. 🚀 If you’re in town make sure to catch up with Andrea McNeal, our VP Business Development! 👋 #jpmorgan #jpm #peptides #ai #drugdiscovery

🚀 Menten AI's Platform launch Today, we’re excited to introduce MAUD 1.0 — our next-generation system for AI-driven design of cyclic peptide medicines. 🎥 Watch a short overview of what we do: youtube.com/watch?v=JbEmzj… #DrugDiscovery #Peptides #GenerativeAI #MAUD #Innovation #AI

Biocom this February 📍 Andrea McNeal, Our VP of Business Development, will be attending to connect with partners and discuss how we’re advancing AI-driven peptide drug discovery. Reach out to set up a meeting! 👋 #peptides #ai #drugdiscovery #partnering

We're excited to share that our CEO, Hans Melo, will be presenting at NextGen Biomed on March 25th, where he’ll discuss Menten AI's platform, MAUD 1.0. 🚀 If you’re attending in London, UK - let’s meet! 👋 #peptides #nextgenbiomed #drugdiscovery #ai